Novel IL-18 cancer inhibition function form short IL-18 and application thereof

By developing short IL-18 protein, using Caspase-3 to cleave IL-18 to form a new functional form, it solved the complex function of IL-18 in tumors, achieved significant tumor suppression effect and survival rate improvement, and provided New treatment options for drug-resistant tumors.

CN119060160APending Publication Date: 2024-12-03INST PASTEUR OF SHANGHAI CHINESE ACADEMY OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310654556.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art has failed to effectively analyze the mechanism of IL-18 in the process of tumor occurrence and development, and IL-18 functions in tumors, making it difficult to develop targeted cancer-suppressing drugs.

Method used

Develop a novel IL-18 protein in the tumor-suppressing functional form of IL-18, which cleaves the IL-18 protein precursor or mature IL-18 through Caspase-3 to form a 15kDa-sized short IL-18 for recruiting NK and NKT cells , activates the STAT1 signaling pathway, enhances the immune response to inhibit tumor growth.

Benefits of technology

It significantly inhibits tumor growth and improves the survival rate of tumor-bearing mice, provides new tumor treatment ideas, and does not rely on the Caspase-1 and IL-18R signaling pathways, and is suitable for drug-resistant tumor types.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004266483120000011
    Figure HDA0004266483120000011
  • Figure HDA0004266483120000012
    Figure HDA0004266483120000012
  • Figure HDA0004266483120000021
    Figure HDA0004266483120000021
Patent Text Reader

Abstract

The invention provides a novel short IL-18 (short IL-18) with a cancer inhibition function form of IL-18 and an application of the short IL-18. Specifically, the invention provides a short IL-18 (short IL-18) protein and multiple uses thereof, especially uses in preparation of drugs for prevention and / or treatment of tumors, and also provides a pharmaceutical composition comprising the short IL-18, uses of the short IL-18 protein and a Caspase-3 protein, and the like. The short IL-18 protein disclosed by the invention has a broad-spectrum recruitment function and a broad-spectrum enhancement function on NK and NKT cells, so that the short IL-18 protein has a universal killing effect on various tumor types.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and more specifically to a novel IL-18 anti-cancer functional form, short IL-18 (shortIL-18), and applications thereof. Background Art

[0002] Interleukin-18 (IL-18) is first expressed in a variety of immune cells and non-immune cells in the form of an inactive precursor pro-IL-18, and is cleaved into biologically active mature IL-18 (matureIL-18) mediated by inflammasomes, and secreted into the extracellular space through the micropores formed on the cell membrane by GSDMD. It then binds to IL-18R on the surface of the target cell and activates downstream signaling pathways such as NF-κB, thereby widely participating in the maintenance of the body's homeostasis and the occurrence and development of various diseases.

[0003] However, there is a lot of contradictory information about the function of IL-18 in tumorigenesis. First, the expression level of pro-IL-18 is closely related to the occurrence and development of cancer, and cancer patients with high expression of pro-IL-18 show a higher survival rate; however, mature IL-18 shows a dual role of tumor suppression and promotion. In addition, because pro-IL-18 has functions that are independent of Caspase-1 and IL-18R in various disease models, and many studies have shown that pro-IL-18 can be cleaved into other forms by various proteases such as proteinase-3, the inventors speculate that IL-18 may have functional forms other than mature IL-18 during the occurrence and development of tumors.

[0004] Therefore, there is an urgent need in this field to analyze the detailed mechanism of IL-18 in the occurrence and development of tumors, and to develop related drugs in a targeted manner to achieve the inhibition of cancer / tumors. Summary of the invention

[0005] The purpose of the present invention is to provide a novel IL-18 anti-cancer functional form of short IL-18 and its application.

[0006] In a first aspect of the present invention, a short IL-18 protein is provided, wherein the amino acid sequence of the short IL-18 protein is selected from the group consisting of:

[0007] (1) the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3;

[0008] (2) an amino acid sequence that is at least 90% (preferably at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) identical to the sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; and / or

[0009] (3) An amino acid sequence obtained by adding, deleting, modifying and / or replacing at least one (e.g., 1 to 4) amino acid residues based on the sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0010] In another preferred embodiment, the short IL-18 protein has an amino acid sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.

[0011] In another preferred embodiment, the molecular weight of the short IL-18 protein is 14 kDa to 15 kDa.

[0012] In another preferred embodiment, the molecular weight of the short IL-18 protein is about 14 kDa or about 15 kDa.

[0013] In another preferred embodiment, the molecular weight of the short IL-18 protein is 14 kDa or 15 kDa.

[0014] In another preferred embodiment, the short IL-18 protein includes a human protein and a non-human mammalian protein.

[0015] In another preferred embodiment, the non-human mammals include: mice, rats, cows, horses, sheep, monkeys, rabbits, or a combination thereof.

[0016] In the second aspect of the present invention, a recombinant protein is provided. The recombinant short IL-18 protein comprises: the short IL-18 protein as described in the first aspect of the present invention and an optional tag protein that assists expression and / or purification.

[0017] In another preferred embodiment, the tag protein includes: Fc tag, HA tag, GGGS linker, FLAG tag, Myc tag, 6His tag, or a combination thereof.

[0018] In the third aspect of the present invention, a polynucleotide is provided, wherein the polynucleotide encodes the short IL-18 protein as described in the first aspect of the present invention, or the recombinant protein as described in the second aspect of the present invention.

[0019] In another preferred example, the polynucleotide has a nucleotide sequence as shown in SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or a corresponding degenerate nucleotide sequence.

[0020] In another preferred example, the polynucleotide has a nucleotide sequence as shown in SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6.

[0021] In the fourth aspect of the present invention, an expression vector is provided, wherein the expression vector contains a single copy or multiple copies of the polynucleotide as described in the third aspect of the present invention.

[0022] In another preferred embodiment, the expression vector is selected from the group consisting of DNA, RNA, viral vectors, plasmids, transposons, other gene transfer systems, or combinations thereof. Preferably, the expression vector comprises a viral vector, such as a lentivirus, adenovirus, AAV virus, retrovirus, or a combination thereof.

[0023] In another preferred embodiment, the expression vector is an adenovirus vector.

[0024] In another preferred embodiment, the expression vector further includes a member selected from the following group: a promoter, a transcription enhancing element WPRE, a long terminal repeat sequence LTR, etc.

[0025] In the fifth aspect of the present invention, a host cell is provided, wherein the host contains the expression vector as described in the fourth aspect of the present invention, or the polynucleotide as described in the third aspect of the present invention is integrated into its genome.

[0026] In a sixth aspect of the present invention, a method for producing a short IL-18 protein is provided, the method comprising the steps of:

[0027] (a) culturing the host cell according to the fifth aspect of the present invention under suitable conditions to obtain a culture containing a short IL-18 protein;

[0028] (b) isolating and / or recovering said short IL-18 protein from said culture; and

[0029] (c) Optionally, purifying and / or modifying the short IL-18 protein obtained in step (b).

[0030] In the seventh aspect of the present invention, a conjugate is provided, wherein the conjugate comprises:

[0031] (a) the short IL-18 protein according to the first aspect of the present invention; and

[0032] (b) a conjugated moiety selected from the group consisting of a detectable label, a toxin, a cytokine, an enzyme, a gold nanoparticle or nanorod, a nanomagnetic particle, a viral coat protein or a VLP, or a combination thereof.

[0033] In another preferred embodiment, the (a) part and the coupling part are coupled via a chemical bond or a linker.

[0034] In another preferred embodiment, the detectable marker comprises a radionuclide.

[0035] In another preferred embodiment, the radionuclide includes a therapeutic isotope selected from the following group: Lu-177, Y-90, Ac-225, As-211, Bi-212, Bi-213, Cs-137, Cr-51, Co-60, Dy-165, Er-169, Fm-255, Au-198, Ho-166, I-10 125, I-131, Ir-192, Fe-59, Pb-212, Mo-99, Pd-103, P-32, K-42, Re-186, Re-188, Sm-153, Ra223, Ru-106, Na24, Sr89, Tb-149, Th-227, Xe-133, Yb-169, Yb-177, or a combination thereof.

[0036] In the eighth aspect of the present invention, an active ingredient is provided, which contains: the short IL-18 protein as described in the first aspect of the present invention, the recombinant protein as described in the second aspect of the present invention, the polynucleotide as described in the third aspect of the present invention, the expression vector as described in the fourth aspect of the present invention, the host cell as described in the fifth aspect of the present invention, the conjugate as described in the seventh aspect of the present invention, or a combination thereof.

[0037] In another preferred embodiment, the active ingredient combination further contains a pharmaceutically acceptable carrier, diluent or excipient.

[0038] In a ninth aspect of the present invention, a medicament is provided, comprising:

[0039] (i) the active ingredient as described in the eighth aspect of the present invention; and

[0040] (ii) a pharmaceutically acceptable carrier, diluent or excipient.

[0041] In another preferred embodiment, the dosage form of the medicament is selected from the following group: injection and lyophilized agent.

[0042] In another preferred embodiment, the medicament comprises 0.01 to 99.99% of the active ingredient as described in the eighth aspect of the present invention and 0.01 to 99.99% of a pharmaceutically acceptable carrier, wherein the percentages are percentages by mass of the medicament.

[0043] In the tenth aspect of the present invention, there is provided use of the active ingredient as described in the eighth aspect of the present invention for preparing a medicament for preventing and / or treating tumors.

[0044] In another preferred embodiment, the tumor includes solid tumors and non-solid tumors (liquid tumors).

[0045] In another preferred embodiment, the tumor includes: colorectal cancer, melanoma, monocytic leukemia, glioblastoma, lung cancer, breast cancer, pancreatic cancer, liver cancer, gastric cancer, kidney cancer, osteosarcoma, cervical cancer, or a combination thereof.

[0046] In the eleventh aspect of the present invention, a pharmaceutical composition is provided, comprising:

[0047] (Z1) the short IL-18 protein as described in the first aspect of the present invention;

[0048] (Z2) IL-18 protein precursor;

[0049] (Z2) mature IL-18 protein;

[0050] (Z3) Chemotherapy drugs;

[0051] (Z4) Caspase-3 enzyme;

[0052] (Z5) Caspase-1 enzyme;

[0053] (Z6) Caspase-3 enzyme promoter or activator;

[0054] (Z7) Caspase-1 enzyme promoter or activator; and / or

[0055] (Z8) a pharmaceutically acceptable carrier, diluent or excipient.

[0056] In another preferred embodiment, the chemotherapy drugs include: Raptinal, Cisplatin, Carboplatin, topoisomerase inhibitor Etoposide, alkylating agent Nitrogen Mustard, anti-mitotic drugs (such as vincristine), or a combination thereof.

[0057] In another preferred embodiment, the chemotherapy drug promotes the activation of Caspase-3 enzyme and / or the production of short IL-18 protein.

[0058] In another preferred embodiment, the Caspase-3 enzyme promoter or activator includes: TNFα, Cycloheximide (CHX), Raptinal, Cisplatin, or a combination thereof.

[0059] In another preferred embodiment, the Caspase-3 enzyme promoter or activator includes: a combination of TNFα and cycloheximide (CHX).

[0060] In another preferred embodiment, the Caspase-1 enzyme promoter or activator includes a variety of substances that can activate inflammasomes.

[0061] In another preferred embodiment, the inflammasome includes: Pyrin inflammasome, NLRP1 inflammasome, NLRP3 inflammasome, NLRC4 inflammasome (IPAF inflammasome), AIM2 inflammasome, or a combination thereof.

[0062] In another preferred embodiment, the Caspase-1 enzyme promoter or activator includes: Nigercin, Imiquimod (R837, Imiquimod), LPS, ATP, Pam3csk4, Muramyl Dipeptide (MDP), Poly (dA-dT), Salmonella, flagellin, anthrax lethal factor LF (lethal factor), bacterial endotoxin (such as Pseudomonas toxin A), bacterial exotoxin, microparticles, or a combination thereof.

[0063] In another preferred example, the Poly (dA-dT) induces activation of AIM2 inflammasome.

[0064] In another preferred example, the Salmonella induces activation of NLRC4 and / or NLRP3 inflammasomes.

[0065] In another preferred embodiment, the flagellin induces activation of the NLRC4 inflammasome.

[0066] In another preferred embodiment, the anthrax lethal factor LF induces activation of NLRP1 inflammasome.

[0067] In another preferred embodiment, the bacterial endotoxin induces activation of Pyrin inflammasome.

[0068] In another preferred embodiment, the Caspase-1 enzyme promoter or activator includes: a combination of LPS and ATP, and a combination of Pam3csk4 and ATP.

[0069] In another preferred embodiment, the amino acid sequence of the IL-18 protein precursor is selected from the following group:

[0070] (1) the amino acid sequence shown in SEQ ID NO:9 or SEQ ID NO:10;

[0071] (2) an amino acid sequence that is at least 90% (preferably at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) identical to the sequence shown in SEQ ID NO: 9 or SEQ ID NO: 10; and / or

[0072] (3) an amino acid sequence obtained by adding, deleting, modifying and / or replacing at least one (e.g., 1 to 4) amino acid residues based on the sequence shown in SEQ ID NO: 9 or SEQ ID NO: 10;

[0073] Furthermore, the amino acid residues selected from the following group in the above amino acid sequence do not have any mutation: D at position 69, D at position 71, and / or D at position 76.

[0074] In another preferred embodiment, the amino acid sequence of the IL-18 protein precursor is shown in SEQ ID NO:9 or SEQ ID NO:10.

[0075] In another preferred embodiment, the amino acid sequence of the mature IL-18 protein is selected from the following group:

[0076] (1) the amino acid sequence shown in SEQ ID NO: 11 or SEQ ID NO: 12;

[0077] (2) an amino acid sequence that is at least 90% (preferably at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) identical to the sequence shown in SEQ ID NO: 11 or SEQ ID NO: 12; and / or

[0078] (3) an amino acid sequence obtained by adding, deleting, modifying and / or replacing at least one (e.g., 1 to 4) amino acid residues based on the sequences shown in SEQ ID NO: 11 or SEQ ID NO: 12;

[0079] Furthermore, the amino acid residues selected from the following group in the above amino acid sequence do not have any mutation: D at position 69, D at position 71, and / or D at position 76.

[0080] In another preferred embodiment, the amino acid sequence of the mature IL-18 protein is shown in SEQ ID NO:11 or SEQ ID NO:12.

[0081] In another preferred embodiment, the pharmaceutical composition comprises:

[0082] (X1) short IL-18 protein;

[0083] (X2) Caspase-3 enzyme;

[0084] (X3) Caspase-3 enzyme promoter or activator; and / or

[0085] (X4) a pharmaceutically acceptable carrier, diluent or excipient.

[0086] In the twelfth aspect of the present invention, there is provided the use of Caspase-3 protein for cleaving IL-18 protein precursor and / or mature IL-18 protein, thereby forming the short IL-18 protein as described in the first aspect of the present invention.

[0087] In another preferred embodiment, the use is for non-diagnostic and non-therapeutic purposes.

[0088] In another preferred embodiment, the molecular weight of the short IL-18 protein is 15 kDa or 14 kDa.

[0089] In another preferred embodiment, the IL-18 protein precursor and / or mature IL-18 protein includes: human protein and non-human mammalian protein.

[0090] In another preferred embodiment, the non-human mammals include: mice, rats, cows, horses, sheep, monkeys, rabbits, or a combination thereof.

[0091] In another preferred embodiment, the motif of the Caspase-3 protein recognizing the mouse IL-18 protein precursor and / or mature IL-18 protein is as shown in SEQ ID NO:7.

[0092] In another preferred embodiment, the motif of the Caspase-3 protein recognizing the human IL-18 protein precursor and / or mature IL-18 protein is as shown in SEQ ID NO:8.

[0093] In another preferred embodiment, the amino acid residues selected from the following group in the amino acid sequences of the IL-18 protein precursor and the mature IL-18 protein do not have any mutations: D at position 69, D at position 71, and / or D at position 76.

[0094] In the thirteenth aspect of the present invention, there is provided the use of short IL-18 protein and Caspase-3 protein for preparing a drug for synergistically treating tumors.

[0095] In the fourteenth aspect of the present invention, a method for preventing and / or treating tumors is provided, the method comprising: administering to a subject in need thereof the active ingredient as described in the eighth aspect of the present invention, the agent as described in the ninth aspect of the present invention, or the pharmaceutical composition as described in the eleventh aspect of the present invention.

[0096] In another preferred embodiment, the subject in need includes mammals, such as humans.

[0097] In another preferred embodiment, the active ingredients related to the short IL-18 protein include: short IL-18 protein, the coding sequence of short IL-18 protein, the expression vector of short IL-18 protein, the host cell expressing short IL-18 protein, the conjugate of short IL-18 protein, or a combination thereof.

[0098] In the fifteenth aspect of the present invention, there is provided a use of a short IL-18 protein for:

[0099] (i) recruitment of NK cells and infiltration of NKT cells;

[0100] (ii) enhance the tumor killing ability of NK cells and NKT cells;

[0101] (iii) Promotes STAT1 in Ser 727 Phosphorylation of the site; and / or

[0102] (iv) Activate the STAT1 signaling pathway and enhance the expression of downstream immune molecules (including but not limited to CCL2, ISG15 and IRF7).

[0103] In another preferred embodiment, the use is for non-diagnostic and non-therapeutic purposes.

[0104] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0105] Figure 1 The presence of short IL-18 forms in the serum of patients with colorectal cancer (CRC) is shown. (A) Kaplan-Meier survival curve. Correlation analysis results between the mRNA expression level of IL-18 and the patient survival rate. According to the expression level, it is divided into two groups: "low" or "high". The X-axis shows the survival time (years) and the Y-axis shows the probability of survival, where 1.0 corresponds to 100%. Data from TCGA. (B) Western blot analysis results of IL-18 in the serum of patients with stage I to IV colorectal cancer.

[0106] Figure 2Pro-IL-18 is shown to be cleaved into short IL-18 under the stimulation of chemotherapeutic drugs. (A) 293T cells were transfected with pro-IL-18 (GST-IL-18-V5) with GST tag fused to the N-terminus and V5 tag fused to the C-terminus, and then stimulated with Raptinal (Rap, 10ng / ml) for 30 minutes and then analyzed by WB. (B) WB detection of the cleavage of endogenous pro-IL-18 in PBMC cells under the stimulation of Rap (10ng / ml, 1h) or Nigericin (Nig, 10uM, 2h). (C) WB detection of the cleavage of endogenous pro-IL-18 in H292 cells under the stimulation of cisplatin (cisp, 20ug / ml, 12h) or Rap (10ng / ml, 1h). (D) WB analysis of the cleavage of endogenous pro-IL-18 in B16-F10 cells under the stimulation of Rap (10ng / ml, 1h).

[0107] Figure 3 It shows that Caspase-3 directly cleaves IL-18 into short IL-18. (A) 293T cells were transfected with mouse pro-IL-18. They were pretreated with the specified caspase inhibitors (pan-Caspase inhibitor z-VAD, Caspase-3 inhibitor z-DEVD-fmk, Caspase-8 inhibitor z-IETD-fmk, 20uM) for 20 minutes and then stimulated with Raptinal (10ng / ml) for 30 minutes. IL-18 cleavage and Caspase-3 cleavage were detected by WB. (B) The effect of shRNA knockdown of Caspase-3 on IL-18 cleavage in response to Raptinal (10ng / ml, 1 hour) was detected in 293T cells. (C) The effect of shRNA knockdown of Caspase-3 on IL-18 cleavage in response to Raptinal (10ng / ml, 30 minutes) was detected in B16-F10 cells. (DF) Recombinant human or mouse full-length or mature IL-18 (2 μg) was incubated with p20 / p10 active form of human or mouse Caspase-3 (rhCASP3 or rmCasp3, 1 unit) at 37°C for 1 hour and then analyzed by Coomassie Brilliant Blue staining.

[0108] Figure 4The sites of Caspase-3 cleavage of mouse and human IL-18 are shown to be D69 and D71 / D76. (AB) 293T cells were transfected with mouse wild-type (WT) IL-18, mutant IL-18 (D35A / D69A) or control empty vector (EV) (Panel A); or transfected with human wild-type IL-18, mutant IL-18 (D36A / D71A / D71A / D71AD76A) or control empty vector (EV) (Panel B), and WB was used to detect the cleavage of IL-18 and Caspase-3 under Rap (10 ng / ml, 30 minutes) stimulation. (C) After 293T cells were transfected with mouse WT or mutant IL-18 (D35A / D69A), cell lysates were collected and incubated with the P20 / P10 active form of mouse Caspase-1 (rmCasp1) (37°C, 1 hour). Western blot analysis showed mature IL-18 and mature IL-1β cleavage. (D) Lysates of 293T cells transfected with human WT or mutant IL-18 (D36A / D71A / D76A) were collected and incubated with the P20 / P10 active form of human Caspase-1 (rhCASP1) or Caspase-3 (rhCASP3) at 37°C for 1 hour. Cleavage of IL-18 and PARP was detected by Western blot analysis. (E) Schematic representation of the cleavage sites of mouse or human IL-18 by Caspase-1 or Caspase-3, respectively.

[0109] Figure 5 The site where Caspase-3 cleaves IL-18 is highly conserved in five species. The IL-18 protein sequences of humans, mice, rats, cattle, and horses were aligned using the UniproUGENE software using the MUSCLE algorithm. The same amino acid residues in the five species are marked with a blue background. The recognition residue site of Caspase-1 (D36 in humans and D35 in mice) is marked with a green box, and the recognition residue site of Caspase-3 (D71 and D76 in humans and D69 in mice) is marked with a red box. * indicates that the amino acid residue site is highly conserved in the five species.

[0110] Figure 6 Figure 2 shows the control of B16-F10 melanoma growth by short IL-18. (AC) In vivo tumor growth (A, C) and final tumor weight (B) of B16-F10 cells stably expressing IL-18WT, IL-18D69A, or a control plasmid (CV) (n = 6 mice per group). (D) B16-F10 tumors expressing IL-18WT and IL-18D69A were harvested at the end of the observation period, and WB analysis of IL-18 cleavage and tubulin control expression in tumor cells was performed. (EF) 0.4×106 B16-F10 tumor cells expressing IL-18 (WT or D69A, n=10 mice) were injected subcutaneously into the right groin of wild-type mice, and tumor growth (B) and survival (C) were assessed daily.

[0111] Figure 7 Shows that tumor cell growth was inhibited by expression of short IL-18. (AC) Growth (A, C) and final tumor weight (B) of B16-F10 tumor cells overexpressing control plasmid, N-terminal or C-terminal IL-18 (short IL-18) in wild-type mice (6 mice per group).

[0112] Figure 8 It shows the therapeutic effect of shortIL-18 on tumors. 2×10 5 B16-F10 cells were injected subcutaneously into the right flank of WT mice; 8 days later, PBS, 1×10 9 pfu of empty adenovirus with GFP tag (adv-V) or adenovirus expressing short IL-18 fused to GFP tag (adv-short IL-18) were injected intratumorally into tumor-bearing mice. Tumors were harvested on day 12 for analysis. Growth (A) or final weight (B) of B16-F10 tumors injected intratumorally with PBS (n=10 mice), adv-V (n=9 mice), or adv-short IL-18 (n=8). (CD) Experimental scheme to examine the effect of short IL-18 on the survival of tumor-bearing mice. 3×10 5 B16-F10 cells were subcutaneously injected into the right flank of WT mice; PBS, 1×10 9 pfu of adv-V or adv-short IL-18 were intratumorally administered to tumor-bearing mice. Survival rates were assessed daily for two months.

[0113] Fig. 9 Shows no difference in the growth of tumors expressing IL-18WT and IL-18D69A in NOG mice. (AC) Growth (A, C) and final tumor weight (B) of B16-F10 tumors overexpressing IL-18WT or IL-18D69A in NOG mice (4 mice per group).

[0114] Fig.10The effect of short IL-18 on immune cells infiltrating into the tumor microenvironment is shown. B16-F10 tumor samples expressing control plasmid (n=5), IL-18WT (n=5) or IL-18D69A (n=6) were collected from tumor-bearing mice on day 14 and used for flow cytometry (FCM) analysis of the infiltration of various immune cells. (AC) The proportion of NK cells infiltrating into the tumor microenvironment (AB) and the proportion of NK cells expressing GZMB or producing IFN-γ (PMA and ionomycin induced, C). (D) Analysis of various immune cells infiltrating into the tumor microenvironment by flow cytometry.

[0115] Fig.11 The inhibitory effect of short IL-18 on tumor cells is shown to be dependent on NK and NKT cells. (AC) Growth (A, C) and final tumor weight (B) of IL-18WT or D69A cells expressing B16-F10 in WT mice treated with isotype control antibody or anti-NK1.1 (anti-NK1.1) (n = 8 mice in IL18 WT-Isotype group; n = 6 mice in IL-18D69A-Isotype, IL-18WT-anti-NK1.1 and IL18 D69A-anti-NK1.1 groups). DETAILED DESCRIPTION

[0116] After extensive and in-depth research, the inventors conducted a large number of analyses on IL-18 in cancer patients and unexpectedly discovered a new functional form of IL-18 for the first time, which they named short IL-18. Direct expression of short IL-18 in tumor cells or intratumoral injection of adenovirus vectors expressing short IL-18 significantly inhibited tumor growth in mice. Further studies have shown that short IL-18 in tumor cells promotes the expression of STAT1 in Ser 727 The phosphorylation of the STAT1 site further activates the STAT1 signaling pathway and enhances the expression of downstream immune molecules such as CCL2, ISG15 and IRF7. CCL2 and other immune molecules are secreted into the tumor microenvironment, recruiting more NK and NKT cell infiltration, and promoting their killing and clearance of tumors. The above in vivo and in vitro experiments verified the tumor suppression function of short IL-18, and analyzed its specific tumor suppression mechanism. On this basis, the present invention was completed.

[0117] the term

[0118] In order that the present disclosure may be more readily understood, certain terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms shall have the meaning given below.

[0119] The term "about" can refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined.

[0120] The term "administering" refers to the physical introduction of the product of the invention into a subject using any of a variety of methods and delivery systems known to those skilled in the art, including intravenous, intratumoral, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, such as by injection or infusion.

[0121] The terms "inflammasome" and "inflammasome" are used interchangeably and refer to multi-protein complexes assembled by intracytoplasmic pattern recognition receptors (PRRs), which are important components of the innate immune system. Inflammasomes can recognize pathogen-associated molecular patterns (PAMPs) or host-derived danger signal molecules (DAMPs), recruit and activate the pro-inflammatory protease Caspase-1. Activated Caspase-1 cleaves the precursors of IL-1β and IL-18 to produce the corresponding mature cytokines. Activation of inflammasomes can also induce cell pyroptosis. The following five inflammasomes have been discovered: Pyrin inflammasome, NLRP1 inflammasome, NLRP3 inflammasome, NLRC4 inflammasome (IPAF inflammasome) and AIM2 inflammasome. It has been determined that a variety of inflammasomes are involved in host defense responses against a variety of pathogens, and pathogens have evolved a variety of corresponding mechanisms to inhibit the activation of inflammasomes. Therefore, it is necessary to develop tumor suppressor mechanisms / functions that are not dependent on Caspase-1 to complement them.

[0122] Short IL-18 protein

[0123] The present invention provides a short IL-18 protein.

[0124] As used herein, the terms "short IL-18" and "short IL-18" are used interchangeably to refer to a new functional form of IL-18, which has a molecular weight of about 15 kDa or 14 kDa, which is different from the mature IL-18 (mature IL-18) with a molecular weight of about 18 kDa and the IL-18 precursor (pro-IL-18) with a molecular weight of about 22 kDa.

[0125] Typically, the amino acid sequence of the short IL-18 protein of the present invention is selected from the group consisting of:

[0126] (1) the amino acid sequence shown in SEQ ID NO: 1;

[0127] (2) an amino acid sequence that is at least 90% (preferably at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) identical to the sequence shown in SEQ ID NO: 1; and / or

[0128] (3) An amino acid sequence obtained by adding, deleting, modifying and / or replacing at least one (e.g., 1 to 4) amino acid residues based on the sequence shown in SEQ ID NO: 1.

[0129] Preferably, the short IL-18 protein has the amino acid sequence shown in SEQ ID NO:1.

[0130] Short IL-18 proteins also include variant forms of the above amino acid sequences with the same or similar functions. These variant forms include (but are not limited to): one or more (usually 1-50, preferably 1-30, more preferably 1-20, and most preferably 1-10) amino acid deletions, insertions and / or substitutions, and addition of one or several (usually within 20, preferably within 10, and more preferably within 5) amino acids at the C-terminus and / or N-terminus. For example, in the art, when amino acids with similar or similar properties are substituted, the function of the protein is usually not changed. For another example, adding one or several amino acids to the C-terminus and / or N-terminus usually does not change the function of the protein. The term also includes active fragments and active derivatives of short IL-18 proteins.

[0131] The variant forms of the short IL-18 protein include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that can hybridize with the encoding DNA of the short IL-18 protein of the present invention under high or low stringency conditions, and polypeptides or proteins obtained using antiserum against short IL-18 protein. The present invention also provides other polypeptides, such as fusion proteins comprising short IL-18 protein or fragments thereof. In addition to almost full-length polypeptides, the present invention also includes fragments of the short IL-18 protein of the present invention.

[0132] In the present invention, "conservative variants of the short IL-18 protein of the present invention" refers to polypeptides formed by replacing at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acids with amino acids having similar or similar properties compared to the amino acid sequence of the short IL-18 protein of the present invention. These conservative variant polypeptides are preferably generated by amino acid substitution according to Table A.

[0133] Table A

[0134] Initial residue Representative replacement Preferred substitutions Ala(A) Val; Leu; Ile Val Arg(R) Lys; Gln; Asn Lys Asn(N) Gln; His; Lys; Arg Gln Asp(D) Glu Glu Cys(C) Ser Ser Gln(Q) Asn Asn Glu(E) Asp Asp Gly(G) Pro; Ala Ala His(H) Asn; Gln; Lys; Arg Arg Ile(I) Leu; Val; Met; Ala; Phe Leu Leu(L) Ile; Val; Met; Ala; Phe Ile Lys(K) Arg; Gln; Asn Arg Met(M) Leu; Phe; Ile Leu Phe(F) Leu; Val; Ile; Ala; Tyr Leu Pro(P) Ala Ala Ser(S) Thr Thr Thr(T) Ser Ser Trp(W) Tyr; Phe Tyr Tyr(Y) Trp; Phe; Thr; Ser Phe Val(V) Ile; Leu; Met; Phe; Ala Leu

[0135] The present invention also provides a polynucleotide molecule or a corresponding degenerate nucleotide molecule encoding the above-mentioned short IL-18 protein or its fragment or its fusion protein. The polynucleotide of the present invention can be in the form of DNA or RNA. The DNA form includes cDNA, genomic DNA or artificially synthesized DNA. The DNA can be single-stranded or double-stranded. The DNA can be a coding strand or a non-coding strand.

[0136] The polynucleotide encoding the mature polypeptide of the present invention includes: a coding sequence encoding only a mature polypeptide; a coding sequence of a mature polypeptide and various additional coding sequences; a coding sequence of a mature polypeptide (and optional additional coding sequences) and non-coding sequences.

[0137] The term "polynucleotide encoding a polypeptide" may include a polynucleotide encoding the polypeptide, or may include a polynucleotide further including additional coding and / or non-coding sequences or a corresponding degenerate nucleotide molecule.

[0138] The present invention also relates to polynucleotides that hybridize with the above-mentioned sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that can hybridize with the polynucleotides of the present invention under stringent conditions. In the present invention, "stringent conditions" refer to: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) the addition of denaturing agents during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, preferably at least 95%. In addition, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.

[0139] The full-length nucleotide sequence of the short IL-18 protein of the present invention or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. A feasible method is to synthesize the relevant sequence by artificial synthesis, especially when the fragment length is short. Generally, a fragment with a very long sequence can be obtained by first synthesizing multiple small fragments and then connecting them. In addition, the coding sequence of the heavy chain and the expression tag (such as 6His) can be fused together to form a fusion protein.

[0140] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the proliferated host cells by conventional methods. The biomolecules (nucleic acids, proteins, etc.) involved in the present invention include biomolecules in isolated form.

[0141] At present, the DNA sequence encoding the short IL-18 protein of the present invention (or its fragment, or its derivative) can be obtained completely by chemical synthesis. Then, the DNA sequence can be introduced into various existing DNA molecules (or vectors) and cells known in the art. In addition, mutations can also be introduced into the sequence of the short IL-18 protein of the present invention by chemical synthesis.

[0142] The present invention also relates to vectors comprising the above-mentioned appropriate DNA sequence and appropriate promoter or control sequence. These vectors can be used to transform appropriate host cells to enable them to express proteins. For example, preferably viral vectors, more preferably adenoviral vectors.

[0143] In the present invention, the inventors unexpectedly discovered for the first time the direct tumor suppressor function of short IL-18 protein. Specifically, the inventors found that directly expressing short IL-18 in tumor cells or intratumorally injecting adenovirus vectors expressing short IL-18 can significantly inhibit tumor growth in mice.

[0144] In addition, the inventors have also explored the tumor suppressor mechanism of short IL-18 protein. Experimental verification shows that the tumor suppressor mechanism of short IL-18 protein depends on the immune response mediated by NK and NKT cells. Short IL-18 can control the growth process of tumors by (i) recruiting more NK and NKT cell infiltration, and (ii) enhancing the tumor killing ability of NK and NKT cells. In view of the broad spectrum of the above recruitment function and enhancement function, that is, short IL-18 can produce the above recruitment and enhancement effects in any type of tumor, so the tumor suppressor effect of short IL-18 is not limited to the tumor types exemplified in the embodiments, but can inhibit a variety of tumor types. As long as the recruitment and enhancement effects occur, the killing effect on the tumor can be achieved at the corresponding tumor location.

[0145] Preferably, the short IL-18 protein of the present invention is particularly effective against tumors that do not involve Caspase-1 and IL-18R, or tumors that are resistant to Caspase-1 and IL-18R related therapeutic agents, because the mechanism of the short IL-18 protein is independent of the function of Caspase-1 and IL-18R.

[0146] In addition, for some tumor types that are resistant or tolerant to T cell immunotherapy, or tumor types that are sensitive to NK immunotherapy, the short IL-18 protein of the present invention and the drugs and pharmaceutical compositions prepared therefrom are potential new treatment options.

[0147] Caspase-3

[0148] Caspase-3 is a caspase-dependent caspase-activating enzyme. In the execution phase of apoptosis, Caspase-3 is activated and plays a key role in initiating cell death. It can catalyze the cleavage of specific protein substrates, leading to typical characteristics of the execution phase of apoptosis, such as nuclear fragmentation and cytoplasmic shrinkage.

[0149] In tumors, the dysfunction of Caspase-3 is closely related to the occurrence, development and responsiveness of tumors to anticancer treatment. On the one hand, the inactivation or defect of Caspase-3 may lead to the blockage of cell apoptosis, allowing cancer cells to escape the restriction of programmed cell death and increase their ability to survive and spread. This may contribute to the development and progression of tumors, making them more invasive and resistant to drugs.

[0150] On the other hand, the activation of Caspase-3 is also widely used in anticancer treatment strategies. Many anticancer drugs and treatments induce apoptosis of cancer cells by activating Caspase-3. The goal of this strategy is to inhibit tumor growth and spread by triggering the self-destruction of tumor cells. Therefore, Caspase-3 is considered an important target in tumor treatment.

[0151] The present invention also provides the use of Caspase-3 protein for cleaving IL-18 protein precursor and / or mature IL-18 protein to form short IL-18 protein.

[0152] In the present invention, the inventors explored the exact amino acid cleavage site of IL-18 (including IL-18 protein precursor and mature IL-18 protein) by Caspase-3 protein, and found that the amino acid site of IL-18 cleavage by Caspase-3 protein is highly conserved among different species (for example, it is highly conserved in five species including human, mouse, rat, cattle and horse, suggesting that the phenomenon of IL-18 cleavage by Caspase-3 may occur in different species).

[0153] Typically, the motif of the Caspase-3 protein recognizing the mouse IL-18 protein precursor and / or mature IL-18 protein is shown in SEQ ID NO:3; the motif of the Caspase-3 protein recognizing the human IL-18 protein precursor and / or mature IL-18 protein is shown in SEQ ID NO:4.

[0154] Furthermore, the amino acid residues selected from the group consisting of D at position 69, D at position 71, and / or D at position 76 in the amino acid sequences of the IL-18 protein precursor and the mature IL-18 protein do not have any mutations.

[0155] Since the amino acid sites where Caspase-3 protein cleaves IL-18 are highly conserved among different species and have a certain degree of universality, Caspase-3 protein can be used to cleave IL-18 protein precursors and / or mature IL-18 proteins of different species and form short IL-18 proteins.

[0156] Uses of Short IL-18 Protein

[0157] In the present invention, various uses of short IL-18 proteins are provided.

[0158] For example, short IL-18 protein can be used to prepare a drug for preventing and / or treating tumors. Typically, the drug contains:

[0159] (i) an active ingredient selected from the group consisting of:

[0160] A short IL-18 protein, a coding sequence of a short IL-18 protein, an expression vector of a short IL-18 protein, a host cell expressing a short IL-18 protein, a conjugate of a short IL-18 protein, or a combination thereof; and

[0161] (ii) a pharmaceutically acceptable carrier, diluent or excipient.

[0162] The tumor includes solid tumors and non-solid tumors (liquid tumors), for example, the tumor includes: colorectal cancer, melanoma, monocytic leukemia, glioblastoma, lung cancer, breast cancer, pancreatic cancer, liver cancer, gastric cancer, kidney cancer, osteosarcoma, cervical cancer, or a combination thereof.

[0163] It should be understood that, as mentioned above, given the broad-spectrum recruitment and enhancement functions of the short IL-18 protein, the tumor suppressor effect of the short IL-18 protein is not limited to the tumor types exemplified in the embodiments, but can suppress a variety of tumor types.

[0164] The uses of the short IL-18 protein also include: the short IL-18 protein and Caspase-3 protein are used to prepare drugs for synergistically treating tumors.

[0165] In addition, the uses of short IL-18 protein include:

[0166] (i) recruitment of NK cells and infiltration of NKT cells;

[0167] (ii) enhance the tumor killing ability of NK cells and NKT cells;

[0168] (iii) Promotes STAT1 in Ser 727 Phosphorylation of the site; and / or

[0169] (iv) Activate the STAT1 signaling pathway and enhance the expression of downstream immune molecules (including but not limited to CCL2, ISG15 and IRF7).

[0170] Those skilled in the art know that the forms of the above short IL-18 protein include but are not limited to: human short IL-18 protein; non-human mammal short IL-18 protein; recombinant short IL-18 protein; and conjugates of short IL-18 protein.

[0171] Pharmaceutical composition

[0172] In the present invention, a pharmaceutical composition is provided, comprising:

[0173] (Z1) short IL-18 protein;

[0174] (Z2) IL-18 protein precursor;

[0175] (Z2) mature IL-18 protein;

[0176] (Z3) Chemotherapy drugs;

[0177] (Z4) Caspase-3 enzyme;

[0178] (Z5) Caspase-1 enzyme;

[0179] (Z6) Caspase-3 enzyme promoter or activator;

[0180] (Z7) Caspase-1 enzyme promoter or activator; and / or

[0181] (Z8) a pharmaceutically acceptable carrier, diluent or excipient.

[0182] Preferably, the pharmaceutical composition comprises:

[0183] (X1) short IL-18 protein;

[0184] (X2) Caspase-3 enzyme;

[0185] (X3) Caspase-3 enzyme promoter or activator; and / or

[0186] (X4) a pharmaceutically acceptable carrier, diluent or excipient.

[0187] The above pharmaceutical composition can be used to prevent and / or treat tumors, and in certain cases, the preventive / therapeutic effect on tumors can have a synergistic effect.

[0188] Methods of prevention and / or treatment

[0189] The present invention provides a method for preventing and / or treating tumors, comprising: administering an active ingredient associated with a short IL-18 protein, or the pharmaceutical composition according to the second aspect of the present invention, to a subject in need thereof.

[0190] Typically, the above-mentioned active ingredients related to the short IL-18 protein include: short IL-18 protein, the coding sequence of the short IL-18 protein, the expression vector of the short IL-18 protein, the host cell expressing the short IL-18 protein, the conjugate of the short IL-18 protein, or a combination thereof.

[0191] Preferably, the dosage of the active ingredients and pharmaceutical compositions related to the short IL-18 protein is a therapeutically effective amount. Those skilled in the art can adaptively adjust the therapeutically effective amount according to actual conditions (including but not limited to dosage form, subject weight, subject disease progression, etc.) in combination with conventional means in the art.

[0192] The above methods also include combination with other tumor prevention / treatment methods.

[0193] Main advantages of the present invention

[0194] 1. The present invention discovered for the first time a new type of IL-18 tumor suppressor functional form - short IL-18, which first provided a more comprehensive and three-dimensional understanding of the functional forms and action mechanisms of IL-18 molecules: in addition to the well-known mature IL-18 functional form produced by Caspase-1 cleavage, pro-IL-18 can also be cleaved by caspase-3 to produce a 15kDa functional sequence, which indicates that IL-18 molecules have multiple different functional forms.

[0195] 2. The present invention found that short IL-18 molecules showed significant anti-cancer effects in various cancers (such as colorectal cancer and melanoma), and significantly improved the survival rate of tumor-bearing mice, which provides a new treatment idea and solution for tumor treatment.

[0196] 3. Because the anti-tumor effect of short IL-18 is achieved by mobilizing NK and NKT cells, shortIL-18 is a potential new treatment option for some tumor types that are resistant or tolerant to T cell immunotherapy, or tumor types that are sensitive to NK immunotherapy.

[0197] 4. Since the tumor suppressor function of short IL-18 does not depend on the Caspase-1 and IL-18R signaling pathways, short IL-18 also has certain application potential for tumor types that are resistant to related therapeutic agents.

[0198] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.

[0199] Example 1 Short IL-18 is present in the serum of CRC patients

[0200] The inventors first analyzed the relationship between the mRNA expression level of IL-18 and the survival rate of colorectal cancer (CRC) patients. The data showed that the mRNA expression level of IL-18 was significantly correlated with the survival rate of CRC patients.

Claims

1. A short IL-18 protein, It is characterized in that The amino acid sequence of the short IL-18 protein is selected from the group consisting of: (1) the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; (2) an amino acid sequence that is at least 90% (preferably at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) identical to the sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; and / or (3) An amino acid sequence obtained by adding, deleting, modifying and / or replacing at least one (e.g., 1 to 4) amino acid residues based on the sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO:

3.

2. A recombinant protein, It is characterized in that The recombinant short IL-18 protein comprises: the short IL-18 protein according to claim 1 and an optional tag protein for facilitating expression and / or purification.

3. A polynucleotide, It is characterized in that The polynucleotide encodes the short IL-18 protein according to claim 1 or the recombinant protein according to claim 2.

4. An expression vector, It is characterized in that The expression vector contains a single copy or multiple copies of the polynucleotide according to claim 3.

5. A host cell, It is characterized in that The host contains the expression vector as claimed in claim 4, or the polynucleotide as claimed in claim 3 is integrated into its genome.

6. A method for producing a short IL-18 protein, It is characterized in that The method comprises the steps of: (a) culturing the host cell according to claim 5 under suitable conditions to obtain a culture containing the short IL-18 protein; (b) isolating and / or recovering said short IL-18 protein from said culture; and (c) Optionally, purifying and / or modifying the short IL-18 protein obtained in step (b).

7. A conjugate, It is characterized in that The conjugate contains: (a) the short IL-18 protein of claim 1; and (b) a conjugated moiety selected from the group consisting of a detectable label, a toxin, a cytokine, an enzyme, a gold nanoparticle or nanorod, a nanomagnetic particle, a viral coat protein or a VLP, or a combination thereof.

8. an active ingredient, It is characterized in that The active ingredient contains: the short IL-18 protein according to claim 1, the recombinant protein according to claim 2, the polynucleotide according to claim 3, the expression vector according to claim 4, the host cell according to claim 5, the conjugate according to claim 7, or a combination thereof.

9. A medicine, It is characterized in that The medicine contains: (i) the active ingredient according to claim 8; and (ii) a pharmaceutically acceptable carrier, diluent or excipient.

10. Use of the active ingredient according to claim 8 for preparing a medicament for preventing and / or treating tumors.